FDA Approval: 1L Amivantamab plus Chemotherapy for EGFR Exon 20 NSCLC
Amivantamab Approved by FDA today, March 1!\n\nIn this episode of Lung Cancer Considered, host Dr. Stephen Liu leads a discussion on the FDA approval of first-line amivantamab plus chemotherapy for NSCLC with an EGFR exon 20 insertion, based on the phase III PAPILLON trial. These data were first shared at ESMO 2023 in Madrid with a simultaneous publication in the New England Journal of Medicine.